Evofem Biosciences Earns New U.S. Patent for SOLOSEC
Evofem Biosciences, Inc. has recently announced that it holds eleven patents listed in the Orange Book that pertain to SOLOSEC through December 2041. This new addition is particularly significant as it solidifies the company's intellectual property surrounding its innovative single-dose treatment designed for bacterial vaginosis and trichomoniasis.
Details of the Latest Patent
The newly awarded U.S. Patent No. 12,280,037, commonly referred to as the '037 patent, encompasses the method and pharmaceutical composition for treating or preventing trichomoniasis. This patent was granted by the U.S. Patent and Trademark Office and is viewed as a critical addition to Evofem's portfolio because it extends SOLOSEC's protection in the market significantly.
Importance of the Patent in Women’s Health
According to Saundra Pelletier, CEO of Evofem Biosciences, the inclusion of this patent in the Orange Book is a crucial step towards not only enhancing their patent portfolio but also building the SOLOSEC brand. SOLOSEC represents the first and only FDA-approved single-dose oral treatment for managing bacterial vaginosis, as well as trichomoniasis in the United States. This patent provides an extended opportunity for healthcare providers and patients to utilize this innovative treatment, ensuring market exclusivity until late 2041.
Understanding SOLOSEC
SOLOSEC, which contains secnidazole as its active ingredient, is designed to treat two prevalent sexual health infections: bacterial vaginosis in females aged twelve and older, and trichomoniasis in individuals aged twelve and older. This unique treatment offers an effective solution by providing a complete course of therapy through a single oral dose, making it significantly easier for patients to adhere to treatment guidelines.
The Challenges of Trichomoniasis
Trichomoniasis is recognized as the most frequently occurring non-viral sexually transmitted infection globally, contributing to approximately 6.9 million new infections in the U.S. annually. Despite its prevalence, the infection often goes undiagnosed due to symptoms that may go unnoticed or due to non-compliance with traditional multi-day treatment regimens.
Investments in Research and Development
In tandem with the patent announcement, Evofem is currently recruiting participants for a Phase 4 clinical trial to explore the effectiveness and cost-effectiveness of SOLOSEC compared to the multi-dose antibiotic metronidazole. This NIH-funded study aims to illuminate the efficiencies and advantages of a single-dose treatment versus the traditional multiple doses.
About Evofem Biosciences
Evofem is focused on addressing unmet needs in women’s sexual and reproductive health through the commercialization of innovative products. With two FDA-approved medications, the company continues to drive forward with innovative solutions that promote better health outcomes.
Future Directions and Investor Relations
Recently, Evofem has filed a preliminary proxy regarding its planned Special Meeting of Stockholders. This meeting will allow stockholders to vote on proposals related to a merger agreement with Aditxt, Inc. and its subsidiary, Adifem, Inc. This strategic move is part of Evofem's efforts to enhance its operational capabilities and expand its market reach.
Company Contact Information
For media inquiries, please contact Evofem at media@evofem.com. Investors and potential partners can reach out to Amy Raskopf, the Chief Business Development Officer, via email at araskopf@evofem.com or by phone at (917) 673-5775.
Frequently Asked Questions
What is SOLOSEC?
SOLOSEC is an FDA-approved, single-dose oral treatment designed to treat bacterial vaginosis and trichomoniasis in individuals aged twelve and older.
What recent patent has Evofem Biosciences received?
Evofem has recently been awarded U.S. Patent No. 12,280,037, which extends its market exclusivity for SOLOSEC through December 2041.
Why is the Orange Book listing important?
The Orange Book listing signifies regulatory approval and provides a foundation for protecting the intellectual property rights of SOLOSEC, ensuring extended market exclusivity for the product.
How does SOLOSEC compare to traditional treatments?
SOLOSEC simplifies treatment with a single dose, potentially increasing patient compliance compared to traditional multi-dose regimens that can lead to missed doses.
What are the next steps for Evofem Biosciences?
Evofem is engaging in further studies and has filed for a proxy to discuss a merger, which may influence its growth and product offerings in the future.
